FEMASYS INC
FEMYNasdaq
$3.01
↓ -1.3%Jul 17 close · end-of-day
Price
1Y↓ -83.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$235.1M
Enterprise Value
$229.7M
P/E
—
P/S
98.9
P/B
32.2
EV/EBITDA
—
PEG
—
FCF Yield
-7.9%
Dividend Yield
—
Revenue (TTM)
$2.4M
Net Income (TTM)
-$11.9M
Free Cash Flow (TTM)
-$18.6M
Gross Margin
—
Operating Margin
-687.9%
Net Margin
-500.0%
ROE
-163.0%
ROIC
-678.5%
Debt / Equity
—
Net Cash
$5.4M
Return 1Y
-83.9%
Company profile
Femasys Inc. focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec. FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing, also commercializes FemVue saline-air device.
- CEO
- Kathy Lee-Sepsick
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 30
- Headquarters
- Georgia
- Website
- femasys.com
Management & directors
- Elefant DovChief Financial Officer
- Lee-Sepsick KathyChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
FEMY Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$424,889.00↑ +24.5%
Diluted EPS$0.00↓ -100.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | $1.2M | $1.2M | $1.1M | $1.6M | $2.3M |
| Gross profit | $731,385.00 | $809,305.00 | $764,280.00 | — | — | — |
| Operating income | -$6.9M | -$8.3M | -$11.6M | -$14.5M | -$17.8M | -$17.6M |
| Net income | -$6.9M | -$7.5M | -$11.4M | -$14.2M | -$18.8M | -$18.6M |
| Diluted EPS | -$7.20 | -$1.12 | -$0.96 | -$0.93 | -$0.85 | -$0.47 |
| Operating cash flow | -$4.9M | -$7.9M | -$10.7M | -$11.3M | -$19.4M | -$18.7M |
| Free cash flow | -$4.9M | -$8.2M | -$11.1M | -$11.4M | -$20.2M | -$19.2M |
| Gross margin | 70.5% | 68.6% | 63.4% | — | — | — |
| Operating margin | -668.0% | -706.7% | -961.7% | -1353.4% | -1091.8% | -767.0% |
| Net margin | -666.2% | -639.0% | -944.6% | -1329.1% | -1155.0% | -812.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $221,484.00 | $554,908.00 | $581,576.00 | $341,264.00 | $409,268.00 | $729,394.00 | $813,387.00 | $424,889.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$4.5M | -$5.1M | -$4.7M | -$5.5M | -$3.9M | -$3.7M | -$4.6M | -$4.2M |
| Net income | -$4.7M | -$5.4M | -$5.1M | -$5.9M | -$4.6M | -$4.2M | -$4.0M | $846,100.00 |
| Diluted EPS | -$0.21 | -$0.24 | -$0.23 | -$0.23 | -$0.16 | -$0.10 | $0.02 | $0.00 |
| Operating cash flow | -$4.3M | -$5.5M | -$5.1M | -$4.8M | -$4.4M | -$5.4M | -$4.2M | -$4.1M |
| Free cash flow | -$4.5M | -$5.9M | -$5.2M | -$4.9M | -$4.4M | -$5.6M | -$4.3M | -$4.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -2023.7% | -922.4% | -812.0% | -1600.1% | -941.1% | -500.9% | -568.3% | -994.0% |
| Net margin | -2115.1% | -974.7% | -881.0% | -1727.9% | -1120.5% | -575.1% | -485.7% | 199.1% |
Company news
May 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-08-27 | Elefant Dov· Chief Financial Officer | I | 38,828 | — | — | filing |
| 2025-08-27 | Lee-Sepsick Kathy· Chief Executive Officer | I | 48,535 | — | — | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.